As drug shortages reach an all-time high in the United States, with 323 active and ongoing shortages reported this year alone, healthcare professionals and patients are facing unprecedented challenges in accessing essential medications. According to data collected by the American Society of Health-System Pharmacists (ASHP), the current total surpasses the previous record of 320 set in 2014, and is the highest recorded since ASHP began tracking shortages in 2001.

The root cause of these shortages is complex and multifaceted, but a significant contributing factor is the profit margins of generic drugs, which are often razor-thin or non-existent. As Ars has reported before, middle managers have driven down wholesale prices to rock-bottom levels, making it unprofitable for manufacturers to produce these essential medications. This has led to several generic manufacturers filing for bankruptcy in recent years.

The shortage of Adderall, a controlled substance used to treat attention-deficit/hyperactivity disorder (ADHD), is a particularly concerning example. The shortage began when a manufacturing delay for one manufacturer caused a shortfall, and it has since been exacerbated by a significant increase in Adderall prescriptions during the pandemic, as well as quotas set by the Drug Enforcement Administration (DEA). According to ASHP, manufacturers of amphetamine products, including Adderall, only sold approximately 70 percent of their allotted quotas in 2022, resulting in a shortage of approximately 1 billion doses.

The lack of transparency from manufacturers regarding the reasons for drug shortages is another significant challenge. In 60 percent of cases, manufacturers do not know or do not provide reasons why their drugs fall into short supply, according to ASHP. This makes it difficult for healthcare professionals and patients to anticipate and plan for shortages, and highlights the need for greater transparency and communication from manufacturers.

To address these shortages and improve supply chains, ASHP has put forth policy recommendations to prevent shortages and improve supply chains, advocating for federal and regulatory changes. These include increasing transparency and communication from manufacturers regarding the reasons for drug shortages, improving the DEA’s quotas for controlled substances, and providing incentives for manufacturers to produce essential medications.

In conclusion, the ongoing drug shortages in the United States are a complex and pressing issue, with far-reaching implications for healthcare professionals, patients, and the pharmaceutical industry as a whole. To address these shortages effectively, it is crucial to understand the root causes and develop targeted solutions that prioritize patient access to essential medications. By working together to improve supply chains and incentivize manufacturers to produce critical drugs, we can mitigate the impact of drug shortages and ensure that patients receive the care they need.